Global Call to Discuss New Data from Partners PrEP and TDF2 PrEP Trials
July 14, 2011Researchers from two different studies of oral pre-exposure prophylaxis (PrEP) announced evidence that both oral tenofovir (TDF, marketed as Viread) and oral tenofovir plus emtricitabine (TDF/FTC, marketed as Truvada) can reduce the risk of HIV transmission among men and women whose primary route of HIV exposure is penile-vaginal sex. These landmark findings, which came from the Partners PrEP and CDC TDF2 trials, extend the benefit previously observed in gay men and transgender women in the iPrEx trial and have the potential to fundamentally change approaches to HIV prevention.
This was a global teleconference convened by AVAC with trial investigators to discuss these findings. Download the recording here (mp3).